Azevan Pharmaceuticals (United States)

Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior

Craig F. Ferris, Shi‐fang Lu, Tara Messenger et al. · Pharmacology Biochemistry and Behavior · 2006 · 105 citations

Behavioral Neuroscience, Medicine, Physiology +5

Azetidinones as vasopressin V1a antagonists

Christophe Guillon, G. A. KOPPEL, Michael Brownstein et al. · Bioorganic & Medicinal Chemistry · 2006 · 73 citations · Full text

Antiparasitic Agent, Medicine, Physiology +6

Neuroradiological Changes Following Single or Repetitive Mild TBI

Praveen Kulkarni, Thomas R. Morrison, Xuezhu Cai et al. · Frontiers in Systems Neuroscience · 2019 · 60 citations · Full text

A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study

Royce J. Lee, Emil F. Coccaro, Henk Cremers et al. · Frontiers in Systems Neuroscience · 2013 · 47 citations · Full text

The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study

Tiffany R. Lago, Michael Brownstein, Emily Page et al. · Psychopharmacology · 2021 · 34 citations · Full text

Experimental Psychopathology, Antagonist Srx246, Psychoneuroimmunology +15